3,4-methylenedioxyamphetamine has been researched along with Amphetamine-Related Disorders in 6 studies
3,4-Methylenedioxyamphetamine: An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally.
Amphetamine-Related Disorders: Disorders related or resulting from use of amphetamines.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Mentions on medical death certificates, last year's ecstasy use, number of drug offenders, seizures, prices and dosage levels figures were used for this descriptive and correlational study." | 1.33 | Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003). ( Corkery, J; Deluca, P; Ghodse, AH; Oyefeso, A; Schifano, F, 2006) |
| " However, it cannot be excluded that co-administration of Pgp inhibitors such as ritonavir or paroxetine could increase MDMA, MDE and PMA bioavailability and also enhance brain entry leading to severe side effects." | 1.32 | P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine. ( Haefeli, WE; Ketabi-Kiyanvash, N; Mikus, G; Weiss, J, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JY | 1 |
| Cheong, JC | 1 |
| Kim, MK | 1 |
| Lee, JI | 1 |
| In, MK | 1 |
| Greene, SL | 1 |
| Kerr, F | 1 |
| Braitberg, G | 1 |
| Schifano, F | 2 |
| Oyefeso, A | 2 |
| Corkery, J | 2 |
| Cobain, K | 1 |
| Jambert-Gray, R | 1 |
| Martinotti, G | 1 |
| Ghodse, AH | 2 |
| Ketabi-Kiyanvash, N | 1 |
| Weiss, J | 1 |
| Haefeli, WE | 1 |
| Mikus, G | 1 |
| Deluca, P | 1 |
| Shima, N | 1 |
| Kamata, H | 1 |
| Katagi, M | 1 |
| Tsuchihashi, H | 1 |
| Sakuma, T | 1 |
| Nemoto, N | 1 |
1 review available for 3,4-methylenedioxyamphetamine and Amphetamine-Related Disorders
| Article | Year |
|---|---|
Review article: amphetamines and related drugs of abuse.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine-Related Disorders; Amphetamines; Benzodiazepines; Charcoa | 2008 |
5 other studies available for 3,4-methylenedioxyamphetamine and Amphetamine-Related Disorders
| Article | Year |
|---|---|
Simultaneous determination of amphetamine-type stimulants and cannabinoids in fingernails by gas chromatography-mass spectrometry.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine; Amphetamine-Related Disorders; Amphetamines; Dronabinol; | 2008 |
Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002.
Topics: 3,4-Methylenedioxyamphetamine; Adolescent; Adult; Amphetamine-Related Disorders; Benzodiazepines; Ca | 2003 |
P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine-Related Disorders; Amphetamines; Animals; ATP Binding Cas | 2003 |
Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003).
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine-Related Disorders; Cause of Death; Crime; Cross-Sectional | 2006 |
Direct determination of glucuronide and sulfate of 4-hydroxy-3-methoxymethamphetamine, the main metabolite of MDMA, in human urine.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamine-Related Disorders; Calibration; Designer Drugs; Gas Chrom | 2007 |